Figueredo PYE, Luna CCM, de León MW, Campos ML, Alfonso BM

Language: Spanish
References: 13
Page: 313-323
PDF size: 513.60 Kb.

ABSTRACT

The monoclonal gammapathies comprise a group of disorders characterized by the abnormal proliferation of a clone of plasmatic cells that are capable of producing a monoclonal paraprotein. The multiple myeloma is the prototype of malignant monoclonal gammapathy its annual incidence is four cases per 100.000 habitants. In a study of 40 patients a monoclonal band was detected by the Hydrasys system, most of them de novo. The most frequent immunoglobulin in this subgroup is immunoglobulin (Ig) G, though slightly less than what Kyle describes for monoclonal gammopathy of Undetermined Significance. As for the multiple myeloma, in the distribution according to the type of Immunoglobulin, we did not find any case of IgM, but we found two of IgD which, according to the information in the literature, is quite infrequent. We present a female patient who was diagnosed with multiple myeloma IgD, although it developed with atypical clinical manifestations.

REFERENCES

1. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-54.

2. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Eng J Med. 1994;330(7):484-9.

3. Bizzaro N, Passini P. Familial occurrence of multiple myeloma and monoclonal gammopathy of undetermined significance in siblings. Hematol. 1990;75(1):58-63.

4. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Hematol. 2007;20(4):637-64.

5. Malpas JS, Bergsagel DE, Kyle RA. Myeloma: Biology and Management. 2da Ed. Oxford, England: Oxford University Press; 1998.

6. Repiso M, Vélez de Mendizábal E, Elizondo MJ. Mieloma múltiple IgA a propósito de un caso. MEDIFAM. 2002;12(2):144-8.

7. Crawford J, Eye MJ, Cohen MJ. Evaluation of monoclonal gammopathy in the well ederly. Am J Med. 1987;82(1):39-45.

8. Alexanian R, Webwe D, Liu F. Differential diagnosis of monoclonal gammopathies. Arch Pathol Lab Med. 1999;123(2):108-13.

9. Blade J, Kyle R, Greipp P. Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch Intern Med. 1997;157(3):361.

10. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Hematol. 2007;20(4):637-64.

11. Conte G, Figueroa G, Lois V, Cabrera M, León A, García H, et al. Mieloma múltipleen. Características clínicas y sobrevida. Rev Med Chilen. 2007;135(9):1111-7.

12. Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungoli Gargantini L, et al. Pronostic factors for malignant transformation in monoclonal gammopath of undetermined signifiance and smoldering multiple myeloma. J Clin Oncol. 2002;20(6):1625-34.

13. Decaux O, Cazalets-Lacoste C, Cador-Rousseau B, Laurat E, Sebillot-Bracq J, Leblay R, et al. Follow-up of monoclonal gammapathy of undetermined significance in a population of 51 patients older than 70 years. Rev Med Int. 2002;23(9):751-8.